Flu outbreak leads to vaccine, drug shortages
The unexpected severity of this year's season has caught drugmakers and pharmacies by surprise.
It's being described as the worst flu outbreak to hit the United States in years. And the rising rate of influenza cases is creating shortages of the drugs and treatments flu sufferers need.
The U.S Centers for Disease Control and Prevention reports widespread influenza activity in 47 states -- with "influenza-like illness" accounting for 4.3% of health provider outpatient visits, compared with last year’s 2.2%.
The CDC says that more than 128 million doses of influenza vaccine have been distributed this flu season and that "some vaccine providers might have exhausted their vaccine supplies" as the outbreak continues.
Roche Holding (RHHBY) tells Reuters there have been supply interruptions of its Tamiflu liquid treatment for children. Tamiflu, which lessens or stops flu symptoms and can shorten the illness, is one of most widely prescribed drugs for the treatment of influenza.
Ryan Wells, a pharmacist in Wichita Falls, Texas, told the Times Record News his store has some Tamiflu in stock but is having trouble keeping up with demand. Wells said as of Thursday some wholesalers were having a shortage of liquid Tamiflu.
"We want to try to make sure that we save it so we have enough supplies for the people that are most at risk," physician Melody Mendiola told WPXI-TV in Pittsburgh. "Elderly people, people with chronic health conditions and the people that are most at risk for being hospitalized."
CVS (CVS) reports "intermittent shortages" of Tamiflu at some of its stores. "It's a combination of the fact that the supplier has had an issue with getting enough liquid Tamiflu in the market and the demand caused by the early influenza season," company spokesman Mike DeAngelis said in an interview with USA Today.
DeAngelis tells MSN Money that high demand is also causing temporary shortages of flu vaccines at some CVS locations. "But we still have vaccine in stock and we resupply our pharmacies and clinics as quickly as possible."
Meanwhile, Sanofi SA (SNYNF), which produces most flu vaccines used in the U.S., told Reuters it has already sold out of two-thirds of its Fluzone seasonal flu vaccine on the unexpected demand.
Another vaccine maker, GlaxoSmithKline (GSK), expects to have its flu vaccine available until the middle of next month.
A spokesman for Walgreen (WAG), one of the nation's largest drugstore chains, told NBC News some of its locations may be experiencing shortages of flu vaccine because of "increased demand for flu shots in recent weeks." Last week, the company reported its pharmacists had administered 5.5 million flu shots so far this season, compared with 5.3 million for last season.
More on Money Now
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
While incompetent bosses like Michael Scott and Andy Bernard typically can’t survive in the workplace, office romances are a very real part of corporate culture.
- Southwest Airlines turns less legroom into $773M
- 'American Idol' gets sorry ratings for season finale
- Powerball's wacky sense of humor
- Millions of Facebook's users are actually pets
- Can crowd funding rescue the LA Times?
- Domino's debuts a DVD that smells like pizza
- Average US retirement age climbs to 61
- McDonald's aims to slim down its 145-item menu
- Bathroom reading goes digital with iPad TP stand
[BRIEFING.COM] The S&P 500 ended this week with a bang, roaring to a new all-time high on the back of stronger-than-expected economic data, influential leadership, and an ongoing appreciation for the Fed's monetary policy support.
The bullish bias was evident in premarket action as the S&P futures pointed to a higher start without the benefit of any definitive news catalyst. Stocks indeed benefited from a blast of buying interest at the opening bell on this ... More
More Market News
All hail the bull market, which ended the week with a big rally. But it also is starting to look a little like 1987, which suffered an epic blow-out.